February 13, 2018 / 1:26 PM / 3 months ago

BRIEF-Trovagene Announces Activation Of Two Additional Clinical Trial Sites To Conduct Early Stage Leukemia Study

Feb 13 (Reuters) - Trovagene Inc:

* TROVAGENE ANNOUNCES ACTIVATION OF TWO ADDITIONAL CLINICAL TRIAL SITES TO CONDUCT ITS PHASE 1B/2 STUDY OF PCM-075 IN PATIENTS WITH AML Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below